EP 3941467 A1 20220126 - COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
Title (en)
COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
Title (de)
KOMBINATIONSTHERAPIE MIT EINEM CHEMOKINREZEPTOR-2(CCR2)-ANTAGONISTEN UND EINEM PD-1 UND/ODER PD-L1-INHIBITOR
Title (fr)
POLYTHÉRAPIE UTILISANT UN ANTAGONISTE DU RÉCEPTEUR 2 DE LA CHIMIOKINE (CCR2) ET UN INHIBITEUR DE PD-1 ET/OU DE PD-L1
Publication
Application
Priority
- US 201916358329 A 20190319
- US 201962950780 P 20191219
- US 2020023722 W 20200319
Abstract (en)
[origin: WO2020191240A1] The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of a central nervous system cancer.
IPC 8 full level
A61K 31/4418 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC (source: EP)
A61K 31/444 (2013.01); A61K 31/519 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2017.12); C07K 16/2818 (2013.01)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020191240 A1 20200924; EP 3941467 A1 20220126; EP 3941467 A4 20221221
DOCDB simple family (application)
US 2020023722 W 20200319; EP 20772952 A 20200319